Related Experiment Video
Updated: May 25, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Amyloid imaging in dementias with atypical presentation
David A Wolk1, Julie C Price, Charles Madeira
1Department of Neurology, University of Pennsylvania, Philadelphia, USA. david.wolk@uphs.upenn.edu
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|January 31, 2012
Summary
Alzheimer's Disease (AD) pathology is common in atypical dementia cases and detectable with amyloid imaging. Brain metabolism patterns, not amyloid presence, correlate with clinical presentation, impacting diagnosis and treatment.
Area of Science:
- Neurology
- Nuclear Medicine
- Radiology
Background:
- Accurate Alzheimer's Disease (AD) biomarkers are crucial for emerging targeted therapies, especially when dementia etiology is unclear.
- Atypical dementia presentations pose diagnostic challenges, necessitating advanced imaging techniques.
Purpose of the Study:
- To evaluate the utility of amyloid positron emission tomography (PET) imaging using Pittsburgh Compound B (PiB) in patients with atypical dementia.
- To investigate the relationship between amyloid deposition, brain metabolism, and clinical phenotypes in these patients.
Main Methods:
- Twenty-eight patients with atypical dementia underwent PiB-PET and [18F]fluoro-2-deoxy-D-glucose (FDG)-PET scans.
- Patients were categorized as PiB-positive, PiB-negative, or PiB-intermediate based on imaging results.
- Analysis included comparing PiB and FDG uptake patterns across different diagnostic categories and clinical phenotypes.
Main Results:
- 39% of patients were PiB-positive, indicating amyloid pathology.
- Amyloid pathology was detected across various atypical diagnoses, including posterior cortical atrophy (PCA) and dementia of uncertain etiology.
- Patterns of cerebral hypometabolism, visualized by FDG-PET, varied by clinical phenotype but were not solely determined by amyloid presence.
Conclusions:
- Amyloid imaging effectively identifies Alzheimer's Disease pathology in patients with atypical dementia presentations.
- Clinical phenotype is more strongly associated with patterns of brain hypometabolism than with the presence or absence of amyloid.
- These findings support the diagnostic and prognostic value of amyloid imaging in complex dementia cases and have implications for future therapeutic strategies.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...